Updates are available Correction dated 2019-10-05
Click to view Correction: https://doi.org/10.1007/s00280-019-03964-6
-
Authors
Rivera, Fernando http://orcid.org/0000-0003-4962-3949
Romero, C.
Jimenez-Fonseca, P.
Izquierdo-Manuel, M.
Salud, A.
Martínez, E.
Jorge, M.
Arrazubi, V.
Méndez, J. C.
García-Alfonso, P.
Reboredo, M.
Barriuso, J.
Muñoz-Unceta, N.
Jimeno, R.
López, C.
- License Information
-
More Information
Article History
Received: 25 February 2019
Accepted: 16 March 2019
First Online: 29 March 2019
Change Date: 5 October 2019
Change Type: Correction
Change Details: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine.
Compliance with ethical standards
:
: FR: Advisory boards, conferences, travel expenses and investigational grants from Roche Pharma, Sanofi, MSD, BMS, Merck-Serono, Bayer, Amgen, Servier and Celgene. CL: Advisory boards, conferences, travel expenses and investigational grants from Roche Pharma and Sanofi. JB: Advisory boards, conferences, travel expenses and investigational grants from Roche Pharma, Novartis, Ipsen, Pfizer, AAA and Celgene.
